Manuscript describes the unique character of a pancreatic endocrine cell population derived from a non-pluripotent stem cell that closely resembles native islets in composition and in vivo function. Dr. William Rust, CEO of Seraxis, will deliver a lecture at the IPITA-IXA-CTRMS Joint Congress on October 29 at 10:00 a.m.

手稿描述了源自非多能干细胞的胰腺内分泌细胞群的独特特征，其在组成和体内功能上与天然胰岛非常相似。Seraxis首席执行官William Rust博士将于10月29日上午10点在IPITA-IXA-CTRMS联合大会上发表演讲。

in San Diego entitled 'Novel stem cell-derived islet-like clusters potently control rodent blood glycemia'. Seraxis will be taking meetings at BIO-Europe, November 6-8, in Munich..

在圣地亚哥题为“新型干细胞衍生的胰岛样簇有效控制啮齿动物血糖”。Seraxis将于11月6日至8日在慕尼黑举行BIO Europe会议。。

GERMANTOWN, MD / ACCESSWIRE / October 26, 2023 / Seraxis, Inc., a regenerative medicine company developing pancreatic islet replacement therapies to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, today announced the publication in bioRxiv of 'Pancreatic Endocrine cell clusters derived from a non-pluripotent stem cell capable of regulating blood glucose in animal models of diabetes.' The manuscript describes a novel population of stem cell-derived pancreatic endocrine cell clusters (SR-02) that form functional pancreatic grafts and potently regulate blood glucose levels in animal models.

GERMANTOWN，MD/ACCESSWIRE/2023年10月26日/Seraxis，Inc.，一家开发胰岛替代疗法的再生医学公司，旨在改变1型和需要胰岛素的2型糖尿病患者的生活，今天在bioRxiv上公布了“源自能够在糖尿病动物模型中调节血糖的非多能干细胞的胰腺内分泌细胞簇”该手稿描述了一种新的干细胞衍生的胰腺内分泌细胞簇（SR-02），其形成功能性胰腺移植物并有效调节动物模型中的血糖水平。

The SR-02 program is the subject of an upcoming IND filing for the treatment of severe recurrent hypoglycemia in patients with T1D. The unique nature of the SR-02 program and the company's clinical goals will be discussed by Dr. William Rust, CEO of Seraxis, at the International Pancreas & Islet Transplantation Association Congress on October 29 in San Diego, and further discussed by Ted Hibben, Chief Corporate Development Officer, at BIO-Europe, November 6-8, in Munich..

SR-02计划是即将提交的用于治疗T1D患者严重复发性低血糖的IND申请的主题。SR-02计划的独特性质和公司的临床目标将由Seraxis首席执行官William Rust博士于10月29日在圣地亚哥举行的国际胰腺和胰岛移植协会大会上讨论，并由Ted Hibben进一步讨论。慕尼黑BIO Europe公司发展总监，11月6日至8日。。

Seraxis

Seraxis

'This manuscript is the first description of a novel population of pancreatic endocrine cell clusters with the potential to be best-in-class as a practical cure for children and adults with insulin-requiring diabetes,' said William Rust.

威廉·拉斯特（William Rust）说：“这份手稿是对新型胰腺内分泌细胞群的首次描述，它有可能成为治疗需要胰岛素的糖尿病的儿童和成人的实用疗法。

ABOUT SERAXIS

关于SERAXIS

Seraxis is bringing transformative cures to the millions of people worldwide struggling with the management and life-threatening complications of T1D and insulin-requiring T2D.

Seraxis正在为全球数百万人努力治疗T1D和需要T2D的胰岛素的管理和危及生命的并发症带来变革性治疗。

Seraxis' lead program, SR-02, is a novel, off-the-shelf islet replacement therapy slated to enter clinical testing with immunosuppressive therapy in 2024 in patients with severe recurrent hypoglycemia. A follow-on diabetes program, SR-03, is a version of the Seraxis pancreatic clusters altered to be unrecognized by the immune system for use by the broader population of T1D and insulin-requiring T2D without chronic immune suppression..

Seraxis的主要项目SR-02是一种新型的现成胰岛替代疗法，预计将于2024年进入免疫抑制治疗的临床试验，用于严重复发性低血糖患者。后续糖尿病计划SR-03是Seraxis胰腺簇的一个版本，被免疫系统识别，供更广泛的T1D和需要T2D的胰岛素人群使用，而无需慢性免疫抑制。。

Seraxis' underlying proprietary technology enables the creation of a pipeline of novel stem cell-derived therapies originating from single donated organs for other indications. The company's lead therapeutic program, SR-02, is manufactured from a stem cell line derived from a human donor pancreas. These cells preferentially re-differentiate into pancreatic clusters containing all the endocrine cells of the native pancreatic islet, and with safety, potency, and manufacturing advantages over embryonic and induced pluripotent stem cells..

Seraxis的基础专有技术可以创建一系列新型干细胞衍生疗法，这些疗法源自单一捐赠器官用于其他适应症。该公司的主要治疗计划SR-02由源自人类供体胰腺的干细胞系制造。这些细胞优先重新分化成含有天然胰岛的所有内分泌细胞的胰腺簇，并且具有优于胚胎和诱导多能干细胞的安全性，效力和制造优势。。

Seraxis is backed by Frazier Life Sciences, Polaris Partners, Eli Lilly, the JDRF T1D Fund and independent investors. Seraxis manufactures its best-in-class therapeutic pancreatic clusters using scalable, clinically compliant processes in its cGMP facility located in Maryland's I-270 Biotech Corridor..

Seraxis得到Frazier Life Sciences，Polaris Partners，Eli Lilly，JDRF T1D基金和独立投资者的支持。Seraxis在位于马里兰州I-270生物技术走廊的cGMP设施中使用可扩展的，符合临床要求的流程，制造一流的治疗性胰腺集群。。

For more information, please visit www.seraxis.com.

欲了解更多信息，请访问www.seraxis.com。

Contact Information

联系信息

Ted Hibben

Ted Hibben

Chief Corporate Development Officer

首席公司发展官员

thibben@seraxis.com

thibben@seraxis.com

SOURCE: Seraxis Inc.

来源：Seraxis Inc。

View source version on accesswire.com:

在AccessWire.com上查看源版本：

https://www.accesswire.com/796509/seraxis-announces-publication-of-preclinical-data-for-a-novel-islet-replacement-therapy-and-clinical-candidate-sr-02-for-insulin-requiring-diabetes-oral-presentation-at-ipita

https://www.accesswire.com/796509/seraxis-announces-publication-of-preclinical-data-for-a-novel-islet-replacement-therapy-and-clinical-candidate-sr-02-for-insulin-requiring-diabetes-oral-presentation-at-ipita